2013 ACR/ARHP Program Book

452 Pages·2013·15.3 MB·English

program
B O O K
Pre-meeting Courses: october 25-26, 2013
oPening leCture and awards: october 26, 2013
sCientifiC sessions: october 26-30, 2013
IMPORTANT SAFETY INFORMATION
imPortant loCations
SERIOUS INFECTIONS CONGESTIVE HEART FAILURE
Patients treated with ENBREL (etanercept) are at increased risk Cases of worsening congestive heart failure (CHF) and, rarely,
aCr office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23A; telephone: [phone] for developing serious infections that may lead to hospitalization new-onset cases have been reported in patients taking ENBREL.
or death. Most patients who developed these infections were Caution should be used when using ENBREL in patients with
attendee lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion taking concomitant immunosuppressants such as methotrexate CHF. These patients should be carefully monitored.
or corticosteroids or were predisposed to infection because of
Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall D Lobby HEMATOLOGIC EVENTS
their underlying disease. ENBREL should not be initiated in the
Rare cases of pancytopenia, including aplastic anemia, some
Career Connection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall F-G, Discovery center - booth 1421 presence of sepsis, active infections, or allergy to ENBREL or fatal, have been reported. The causal relationship to ENBREL
its components. ENBREL should be discontinued if a patient
Child Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .call for Location; telephone: [phone] develops a serious infection or sepsis. Reported infections therapy remains unclear. Exercise caution when considering
ENBREL in patients who have a previous history of significant
Clinical trials Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion include: 1) Active tuberculosis (TB), including reactivation of hematologic abnormalities. Advise patients to seek immediate
latent TB. Patients with TB have frequently presented with
medical attention if they develop signs or symptoms of blood
Coat/Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Under Hall D escalator disseminated or extrapulmonary disease. Patients should be
dyscrasias or infection. Consider discontinuing ENBREL if
tested for latent TB before ENBREL use and periodically during
Concierge Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion significant hematologic abnormalities are confirmed.
therapy. Treatment for latent infection should be initiated prior
discovery Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall F-G, booth 1421 to ENBREL use, 2) Invasive fungal infections, including HEPATITIS B VIRUS REACTIVATION
histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, Use of TNF blockers, including ENBREL, has been associated
exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Exhibit Hall F-G blastomycosis, and pneumocystosis. Patients with histoplasmosis with reactivation of hepatitis B virus (HBV) in chronic carriers of
or other invasive fungal infections may present with disseminated, this virus. The majority of these reports occurred in patients on
first aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .box office G rather than localized, disease. Antigen and antibody testing for concomitant immunosuppressive agents, which may also
foundation Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall F-G, Discovery center - booth 1421 histoplasmosis may be negative in some patients with active contribute to HBV reactivation. Exercise caution when considering
infection. Empiric antifungal therapy should be considered ENBREL in patients identified as carriers of HBV.
foundation donors’ lounge . . . . . . . . . . . . . . . . . . . . . . . . . . .24b-c in patients at risk for invasive fungal infections who develop ALLERGIC REACTIONS
graffiti walls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion and Exhibit Hall F-G severe systemic illness, and 3) Bacterial, viral, and other Allergic reactions associated with administration of ENBREL
infections due to opportunistic pathogens, including Legionella during clinical trials have been reported in <2% of patients. If
Hotel reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion and Listeria. an anaphylactic reaction or other serious allergic reaction occurs,
The risks and benefits of treatment with ENBREL should be administration of ENBREL should be discontinued immediately
industry-supported symposia information . . . . . . . . . . . . . .Hall D Lobby
carefully considered prior to initiating therapy in patients 1) with and appropriate therapy initiated.
innovation theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Hall F-G, booth 731 chronic or recurrent infection, 2) who have been exposed to TB, IMMUNIZATIONS
3) who have resided or traveled in areas of endemic TB or endemic Live vaccines should not be administered to patients on ENBREL.
lost and found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Acr office (23A)
mycoses, or 4) with underlying conditions that may predispose JIA patients, if possible, should be brought up to date with all
membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion them to infections such as advanced or poorly controlled diabetes. immunizations prior to initiating ENBREL. In patients with exposure
Patients should be closely monitored for the development of signs to varicella virus, consider temporary discontinuation of ENBREL
newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26A-b; telephone: [phone] and symptoms of infection during and after treatment with and prophylactic treatment with Varicella Zoster Immune Globulin.
ENBREL, including the possible development of TB in patients
nursing mothers’ room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7A AUTOIMMUNITY
who tested negative for latent TB prior to initiating therapy.
Autoantibodies may develop with ENBREL, and rarely lupus-like
overflow rooms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25b (San Diego convention center) MALIGNANCIES syndrome or autoimmune hepatitis may occur. These may resolve
308 (Hilton San Diego bayfront center) Lymphoma and other malignancies, some fatal, have been upon withdrawal of ENBREL. Stop ENBREL if lupus-like
reported in children and adolescent patients treated with tumor syndrome or autoimmune hepatitis develops.
Poster Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Exhibit Hall B2-C-D necrosis factor (TNF) blockers, including ENBREL.
WEGENER’S GRANULOMATOSIS PATIENTS
Prayer room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21 In adult clinical trials of all TNF blockers, more cases of The use of ENBREL in patients with Wegener’s granulomatosis
lymphoma were seen compared to control patients. The risk of receiving immunosuppressive agents (eg, cyclophosphamide) is
recharge areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall F-G,
lymphoma may be up to several-fold higher in RA and psoriasis not recommended.
Attendee Lounge (Sails Pavilion) patients. The role of TNF blocker therapy in the development of
MODERATE TO SEVERE ALCOHOLIC HEPATITIS
malignancies is unknown.
registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sails Pavilion Based on a study of patients treated for alcoholic hepatitis,
Cases of acute and chronic leukemia have been reported in exercise caution when using ENBREL in patients with moderate
restaurant reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall B Lobby and Sails Pavilion association with postmarketing TNF blocker use in RA and other to severe alcoholic hepatitis.
indications. The risk of leukemia may be higher in patients with
ribbon distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .registration (Sails Pavilion) ADVERSE EVENTS
RA (approximately 2-fold) than the general population.
The most commonly reported adverse events in RA clinical trials
SessionSelect lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall D Lobby (Monday – Wednesday) Melanoma and non-melanoma skin cancer (NMSC) have been were injection site reaction, infection, and headache. In clinical
shuttle Bus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall E Lobby reported in patients treated with TNF blockers, including trials of all other adult indications, adverse events were similar
ENBREL. Periodic skin examinations should be considered for all to those reported in RA clinical trials.
simple tasks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .exhibit Halls F-G, Discovery center - booth 1421 patients at increased risk for skin cancer.
DRUG INTERACTIONS
speaker ready room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22 Pediatric Patients The use of ENBREL in patients receiving concurrent
In patients who initiated therapy at ≤18 years of age, approximately cyclophosphamide therapy is not recommended. The risk of
technology Center (Cme/internet) . . . . . . . . . . . . . . . . . . . . .Sails Pavilion half of the reported malignancies were lymphomas (Hodgkin’s serious infection may increase with concomitant use of abatacept
Visitor information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall B Lobby and non-Hodgkin’s lymphoma). Other cases included rare therapy. Concurrent therapy with ENBREL and anakinra is not
malignancies usually associated with immunosuppression and recommended. Hypoglycemia has been reported following
wheelchairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . order through ScootAround, Inc.; malignancies that are not usually observed in children and initiation of ENBREL therapy in patients receiving medication for
telephone: [phone]. (the San Diego adolescents. Most of the patients were receiving concomitant diabetes, necessitating a reduction in antidiabetic medication in
immunosuppressants. some of these patients.
convention center does not provide
NEUROLOGIC EVENTS
wheelchairs for general use.) Treatment with TNF-blocking agents, including ENBREL, has Please see Brief Summary of Prescribing Information on
preceding pages.
wi-fi way . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Exhibit Hall F-G been associated with rare (<0.1%) cases of new onset or
exacerbation of central nervous system demyelinating disorders,
References: 1. Enbrel® (etanercept) Prescribing Information, June 2013.
some presenting with mental status changes and some associated
2. Data on file, Amgen Inc. #1 Biologic for Rheumatologists, 2013.
special needs with permanent disability, and with peripheral nervous system 3. Data on file, Amgen Inc. TEMPO CSR 57599 3 yr Clinical 06/2005.
demyelinating disorders. Cases of transverse myelitis, optic
If you require special arrangements, please contact the Acr office (23A); telephone: [phone] .
neuritis, multiple sclerosis, Guillain-Barré syndromes, other
emergency Contact information peripheral demyelinating neuropathies, and new onset or
exacerbation of seizure disorders have been reported in
Space is provided on the back of your badge to list name and telephone numbers of your emergency
postmarketing experience with ENBREL therapy. Prescribers
contacts. Please complete this information before inserting your badge in your badge holder. should exercise caution in considering the use of ENBREL in
patients with preexisting or recent-onset central or peripheral
nervous system demyelinating disorders. 75474-R1-V1
Pg 3 051_36588 C M Y K Job Number: 20117
Revision No: 1
Date: 8/6/13
program
B O O K
ABOUT THE ANNUAL MEETING
Participation Statement
This annual meeting is sponsored by the American College of Rheumatology for educational purposes only. The material
presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed,
but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare
professionals at arriving at their own conclusions and consequent application. Attendees participating in this medical
education program do so with full knowledge that they waive any claim they may have against the College for reliance on
any information presented during these educational activities. The College does not guarantee, warrant or endorse any
commercial products or services.
The ACR’s CME purpose is to provide comprehensive education to improve the knowledge and performance of physicians,
scientists and other health professionals. The ACR will offer evidence-based educational activities designed to enhance
practice performance and improve the quality of care in those with or at risk for arthritis and rheumatic and musculoskeletal
diseases.
Global Learning Objectives
At the conclusion of the 2013 ACR/ARHP annual meeting, participants should be able to:
• identify recent developments in the diagnosis and management of patients with rheumatic diseases
• outline new technologies for the treatment of rheumatologic problems
• describe potential challenges in the delivery of care to patients with rheumatic diseases and to specify
possible solutions
• utilize new research data to improve the quality of care of patients with rheumatic diseases
• summarize recent rheumatology research findings
The program is the result of a planning process that identified educational needs to change or enhance the knowledge,
competence or performance of rheumatology professionals. The program’s content was derived from both needs assessment
and practice gap analysis that took professional activities, practice setting, ABIM recertification requirements and physician
attributes into account.
Printing of this publication is supported by Amgen, Inc.
This publication was printed by an FSC validated printer on eco-friendly paper.
TABLE OF CONTENTS
POLICIES ACR Basic Research Conference: Beyond Germline Genetics:
New Perspectives on Rheumatic Disease Predisposition –
Copyright Materials Policy .....................................11
Day One ....................................................23
Media ......................................................11
ACR Clinical Research Conference: Preclinical Rheumatic Disease –
Embargo Policy ...............................................11 Day One ....................................................24
ACR/ABIM Maintenance of Certification Learning Session –
MEETING INFORMATION
2013 Update in Rheumatology .................................25
Cell Phones, PDAs & Other Electronic Devices .....................12
Saturday, October 26, 2013
Children ....................................................12
ACR Musculoskeletal Ultrasound Course for Rheumatologists –
Child Care ...................................................12
Fundamentals – Day Two ......................................25
Nursing Mothers’ Room .......................................12
ACR Clinical Research Conference: Preclinical Rheumatic Disease –
Registration .................................................12
Day Two ....................................................26
Exhibit Hall ..................................................12
ACR Review Course ...........................................27
Meeting Room Capacity/Imortant First Safety Information ...........12
ACR Basic Research Conference: Beyond Germline Genetics:
Photoograpy and Videotaping ..................................12 New Perspectives on Rheumatic Disease Predisposition –
Name Badges ................................................12 Day Two ....................................................28
No Smoking .................................................12 ARHP Clinical Focus Course: Meeting the Challenges of Measuring
Outcomes in Rheumatology Clinical Practice ......................29
MEETING NAVIGATION GUIDE ACR Practice Management Pre-Meeting Course ....................30
Track Icons ..................................................13
ACR/ARHP ANNUAL MEETING PROGRAM
Session Formats ..............................................13
Abstract Formats .............................................14 SCIENTIFIC SESSIONS
Abstract Categories ...........................................14
Saturday, October 26, 2013
MEETING SERVICES ACR/ARHP Opening Lecture and Awards ..........................31
My Annual Meeting ..........................................17 ACR/ARHP Champagne Reception ...............................31
Discovery Center .............................................17
Sunday, October 27, 2013
Membership Booth ...........................................17
ACR Sessions
Lost and Found ...............................................18
Newsroom ..................................................18 ACR Pediatric Rheumatology Town Hall Meeting ...................32
Attendee Lounge .............................................18 Adult Onset Still’s Disease: A Clinical Review from Pathophysiology
to Therapies ................................................32
Concierge Center .............................................18
Career Connection ............................................18 ACR Session
Shuttle Bus ..................................................18 Year in Review ...............................................32
Speaker Ready Room ..........................................18
ACR Sessions
Wi-Fi Way and Recharge Access .................................18
Macrophage Polarization ......................................32
Rheumatology Research Foundation Donors’ Lounge ...............18
Patient Engagement/Privacy and Security .........................32
SPECIAL OFFERS ARHP Networking Event
SessionSelect ................................................19 ARHP First-time Attendee Orientation ............................32
What Would Make the Meeting Better ...........................20 ACR Meet the Professor Sessions
Medical Bag .................................................20 Antiphospholipid Syndrome (001) ...............................33
Crystal: Diagnosis and Management of Gout (002) .................33
POSTER SESSIONS
Dermatological Manifestations of Rheumatic Diseases (003) .........33
Poster Session Presenter Instructions ............................20 Pediatric Systemic Lupus Erythematosus (004) .....................33
Poster Preseter No-shows ......................................20 Pediatrics: Spondylarthritis in Children (005) ......................33
Guided Poster Tours ...........................................20 Psoriatic Arthritis (006) ........................................33
Rheumatoid Arthritis: Challenging Cases (007) .....................33
PRE-MEETING PROGRAM
Rheumatoid Arthritis: Outcome Measures in Clinical Practice (008) ...33
Spondylarthropathy: An Update (009) ............................33
Friday, October 25, 2013
Systemic Lupus Erythematosus: Novel Treatments (010) .............33
ACR Musculoskeletal Ultrasound Course for Rheumatologists –
ACR Workshops
Fundamentals – Day One ......................................21
Histopathology of Rheumatic Lung Disease (201). . . . . . . . . . . . . . . . . . . 34
ACR Certified Rheumatology Coder Course ........................22
Magnetic Resonance Imaging in the Diagnosis and Management
of Spondyloarthritis: A Clinician’s Guide (202) .....................34
Muscle Involvement in Rheumatic Diseases (203) ..................34
2 2013 Program Book
TABLE OF CONTENTS
ARHP Networking Event Cutaneous Vasculitis (013) .....................................42
ARHP Moderator Orientation ...................................34 Fibromyalgia 2013: Update on Management (014) .................42
Hereditary Angioedema Update (015) ............................42
ACR Sessions
Inflammatory Eye Disease/Uveitis (016) ..........................42
Legislative Update From Capitol Hill .............................34
Reactive Arthritis: An Update (017) ..............................42
Medical Education: The Year in Review ...........................34
Scleroderma Mimics (018) .....................................42
Where’s the Money? A Comprehensive Approach to Funding Your
Systemic Lupus Erythematosus: Lupus Nephritis (019) ..............42
Research ...................................................34
Understanding of Approach to the Care of Patients with
ACR Poster Session A and Poster Tours Vasculitis (020) ..............................................42
Abstracts (#1-760) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
ACR Sessions
ACR Sessions Alopecia 101 for the Rheumatologist .............................42
CORC FORUM: Disaster Planning: How to Prepare for a Catastrophe Mechanisms of Pain in Osteoarthritis ............................43
and Minimize your Liability ....................................35 Telomeres, Telomerase and Age-Related Disease ...................43
Inflammation and Atherosclerosis: Autoimmunity and
ACR Workshops
Cardiovascular Disease ........................................35
Beyond Musculoskeletal Ultrasound for Rheumatologists (209) .......43
New Therapies for Modulating Cell Signaling in
Rheumatoid Arthritis .........................................35 Clinical Anatomy and Physical Exam: Essential Tools in Lower
Rheumatology Research Foundation Memorial Lecture: Pediatric Extremity Regional Pain Syndromes (210) ........................43
Rheumatology - Where We’ve Been, Where We’re Going ...........36 Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry
Rheumatology Research Foundation Oscar S. Gluck, MD, and Clinical Risk Factors: The New Fracture Risk Assessment
Algorithm (211) ..............................................43
Memorial Lectureship: The Contribution of Bone to Whole
Organism Physiology .........................................36 ACR Sessions
The Link Between Inflammation in the Joint and the Gut ............36 Molecular Mechanisms of Muscle Dysfunction in Inflammatory
Update on Thrombotic Microangiopathies ........................36 Myopathy and Muscular Dystrophy .............................43
ARHP Session Osteoarthritis Pathophysiology, Diagnosis and Management:
What Can I Tell my Osteoarthritis Patient to Do Other Than
Keynote Address: Words that Heal ...............................36
Weight Loss and Quadriceps Strengthening? ......................43
Exhibits and Innovation Theater Sentinels of the Immune System: Dendritic cell and Plasmacytoid
See page 352 for the complete Innovation Theater listing. Dendritic Cells ...............................................44
The Great Debate: Biologics or Triple Therapy for the Treatment
ACR Workshops
of Rheumatoid Arthritis? ......................................44
Advanced Musculoskeletal Ultrasound (204) ......................37
Vascular Disease in Scleroderma: A Multi-Organ Challenge ..........44
Basic Statistical Concepts for the Medical Researcher (205) ..........37
ACR Concurrent Abstract Sessions
Dermatopathology of Rheumatic Diseases (206) ...................37
Peripheral Magnetic Resonance Imaging in Rheumatology Biology and Pathology of Bone and Joint I: Cartilage Biology and
Practice (207) ...............................................37 Osteoarthritis (#766-771) .....................................44
Physical Examination Skills for Improved Detection of Synovitis Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and
and Cervical Thoracolumbar Disorders (208) ......................37 Angiogenesis I: Identifying Novel Factors that Facilitate
Neovascularization and Cell Trafficking (#772-777) .................45
ARHP Sessions
Epidemiology and Health Services Research I: Comorbidities in
Health Literacy Universal Precautions for the Rheumatic Diseases (#778-783) ................................45
Rheumatology Setting ........................................37
Miscellaneous Rheumatic Diseases (#784-789) ....................46
Immunology Boot Camp Session 1: The Basics of
Pediatric Rheumatology: Clinical and Therapeutic Disease: Juvenile
Targeted Therapies ...........................................37
Idiopathic Arthritis (#790-795) .................................47
Mediation Analysis: Theory and Method for Causal Inference ........38
Rheumatoid Arthritis - Clinical Aspects I: Treatment Strategies in
ACR Plenary Session I: Discovery 2013 Rheumatoid Arthritis (#796-801) ...............................47
Abstracts (#761-765) ..........................................38 Rheumatoid Arthritis Treatment - Small Molecules, Biologics
and Gene Therapy: Safety Issues (#802-807) ......................48
ACR Sessions
Rheumatoid Arthritis- Autoantibodies and Citrullinated
Opportunities for Social Media in Medical Education ...............40 Proteins (#808-813) ..........................................49
Why Every U.S. Rheumatologist Should Join the National Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects
Rheumatology Registry (RISE) ..................................41 and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis
ARHP Networking Event (#814-819) ..................................................49
Systemic Sclerosis, Fibrosing Syndromes and Raynaud’s –
Networking Forum ............................................41
Pathogenesis, Animal Models and Genetics I: Therapeutic
ACR Session Interventions in Preclinical Animal Models of Scleroderma
ACR Knowledge Bowl- Preliminary Round .........................41 (#820-825) ..................................................50
ACR Meet the Professor Sessions ACR/ARHP Combined Abstract Session
Adult Inflammatory Myopathy (011) .............................41 ACR/ARHP Combined Rehabilitation Abstract Session (#826-831) .....51
Behçet’s Disease (012) ........................................42
2013 Program Book 3
TABLE OF CONTENTS
ARHP Sessions ARHP Sessions
Best Practices for Diagnostic Imaging in Evaluating Rheumatologic “Fine Tuning” Your Skills in Utilizing Disease Activity Measurement
Conditions ..................................................51 Tools for Rheumatic Arthritis ...................................63
Influence of Cardiac Comorbidities on Exercise in Individuals Postural Changes: How to Improve Joint Protection, Strength and
With Rheumatic Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 Gain Efficiency ...............................................63
Juvenile Systemic Lupus Erythematosus ..........................52 Rheumatic Disease Update: Myositis, An Overview and Differentiation
ARHP Concurrent Abstract Session From Metabolic Myopathies ...................................63
ARHP Exemplary Abstracts (#832-837) ...........................52 ARHP Concurrent Abstract Sessions
ACR Workshops Epidemiology and Public Health (#897-902) .......................63
Joint Injection Techniques (212) .................................53 Psychology/Social Sciences (#903-908) ...........................64
Musculoskeletal Exam Skills I: General Musculoskeletal Examination Industry-Supported Symposia ..............................352
for Arthritis (213) ............................................53
Monday, October 28, 2013
Musculoskeletal Ultrasonography: Basic (214) .....................53
Synovial Fluid Analysis and Crystal Identification (215) ..............53 ACR Sessions
ACR Sessions Clinicopathologic Conference: A Patient With Rheumatoid Arthritis
OA-OMICS ...................................................53 and Systemic Disease .........................................65
Pediatric Inflammatory Brain Diseases ...........................53 Interleukin (IL-6), The Pleiotrophic Cytokine: New Clinical Roles and
Quality Measures in Rheumatology: Developing and Implementing Therapeutic Opportunities .....................................65
Meaningful Measures as Health Care Reform Advances .............53 Medical Marijuana and the Rheumatologist .......................65
Regenerative and Stem Cell Medicine ............................54
Mitigating Health Disparities in Rheumatologic Disease .............65
Sex and Autoimmunity: Hormones and Beyond ....................54
Tyro3/Axl/Mer (TAM) Receptors and Innate Immune Regulation ......65
Thieves’ Market: Show Me Your Best Cases .......................54
ARHP Sessions
ACR Concurrent Abstract Sessions
An Overview of Qualitative Research .............................66
Fibromyalgia, Soft Tissue Disorders and Pain: Diagnosis and
Disease Epidemiology (#838-843) ...............................54 Immunology Boot Camp Session 2: The Basics of Autoimmunity
Health Services Research, Quality Measures and Quality of Care - and Immunodeficiency - When “Good Cells Go Bad” ...............66
Pediatrics, Immunization and Choosing Wisely (#844-849) ..........55 Piloting Your Research to Success: The Why, What and How of
Imaging of Rheumatic Diseases: Imaging in Vascular and Pilot Studies ................................................66
Extra-articular (#850-855) .....................................55
ACR Session
Metabolic and Crystal Arthropathies I (#856-861) ..................56
Improving Quality, Outcomes and Spending in Health Care:
Osteoporosis and Metabolic Bone Disease: Clinical Aspects
Good Data and Measures Are Just the Beginning ..................66
and Pathogenesis (#862-867) ..................................57
Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid ACR Meet the Professor Sessions
Arthritis in At-Risk Populations (#868-873) .......................57 Antiphospholipid Syndrome (031) ...............................66
Rheumatoid Arthritis Treatment - Small Molecules, Biologics and
Calcium Crystal Arthritis (032) ..................................66
Gene Therapy: Efficacy of Approved Biologics II (#874-879) ..........58
Controversies in Sjögren’s Syndrome (033) ........................67
Systemic Lupus Erythematosus - Clinical Aspects and Treatment:
Dermatological Manifestations of Rheumatic Diseases (034) .........67
Lupus Nephritis and Genetics (#880-885) ........................59
Systemic Lupus Erythematosus - Human Etiology and Infections With Biologics (035) ..................................67
Pathogenesis I (#886-890) - 2012 Lee C. Howley, Sr. Prize for Arthritis Pediatrics: Periodic Fevers in Children (036) .......................67
Research Introductory Talk .....................................60
Pregnancy and Rheumatic Diseases (037) .........................67
Vasculitis I (#891-896) .........................................61
Systemic Lupus Erythematosus: Central Nervous System (038) .......67
ACR Meet the Professor Sessions
Vasculitis Mimics (039) ........................................67
Ankylosing Spondylitis: 2013 Update (021) ........................62
Vitamin D and Bone Health (040) ................................67
Crystal: Diagnosis and Management of Gout (022) .................62
ACR Workshops
Juvenile Dermatomyositis (023) .................................62
Osteoarthritis: Update 2013 (024) ...............................62 Clinical Anatomy and Physical Exam: Essential Tools in Upper
Extremity Regional Pain Syndromes (216) ........................67
Pain: Evaluation and Treatment of Back Pain (025) .................62
Rheumatoid Arthritis: Biological Agents (026) .....................62 Musculoskeletal Ultrasonography: Basic (217) .....................68
Rheumatoid Arthritis: Challenging Cases (027) .....................62 X-ray Challenges in Rheumatic Diseases (218) .....................68
Systemic Lupus Erythematosus: Novel Treatments (028) .............62 ACR Sessions
Systemic Sclerosis: Disease Staging and Subsetting in
Atypical Myopathies ..........................................68
Clinical Practice (029) .........................................63
Good Reviewers Make Good Authors: A Guide to Conducting
Vasculitis: Update (030) ........................................63
Excellent Manuscript Reviews ..................................68
Kawasaki Disease: Putting Out the Fire ...........................68
Rheumatology Research Foundation Special Session: Clinician
Scholar Educators ............................................68
4 2013 Program Book
TABLE OF CONTENTS
ACR/ARHP Poster Session B, Thieves’ Market Posters ACR Sessions
and Poster Tours Behçet’s Disease .............................................77
Abstracts (#909-1689) ........................................69 Winning at Clue: The Clinical Rheumatologist’s Guide to
Figuring out Who Killed Who, With What and Where in the
ACR Sessions
Rheumatic Diseases ..........................................77
How to Maintain Your Medical License and Certification After 2013:
ACR Workshops
Changes Will Impact All Physicians. Are You Prepared? .............70
Magnetic Resonance Imaging in the Diagnosis and Management
Poor Sleep: Consequences and Cures ............................70
of Spondyloarthritis: A Clinician’s Guide (223) .....................77
ARHP Session
Peripheral Magnetic Resonance Imaging in Rheumatology
Distinguished Lecturer: Integrating Concepts of Behavioral Change and Practice (224) ...............................................77
Technology to Promote Health in Persons With Arthritis ............70 Synovial Fluid Analysis and Crystal Identification (225) ..............78
Exhibits and Innovation Theater ACR Session
See page 352 for the complete Innovation Theater listing. Autoimmunity Caused by Immune Deficiency: When Not Enough
Is Too Much .................................................78
ACR/ARHP Workshops
Crystal Diseases: How Does Joint Damage Occur and Why do
Dermatopathology of Rheumatic Diseases (219) ...................70
Attacks Resolve Spontaneously? ................................78
Joint Injections (Knee, Ankle, Shoulder and Wrist) (220) .............70
Curbside Consults - Ask the Experts ..............................78
Musculoskeletal Exam Skills II: Regional Musculoskeletal
Functional Genomics: Approaches to Identifying Causal Variants ......78
Examination of the Neck and Low Back (221) .....................71
Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis ...............78
Renal Histopathology in Systemic Lupus Erythematosus and
Vasculitis (222) ..............................................71 ACR Concurrent Abstract Sessions
ACR Sessions Epidemiology and Health Services Research II: Epidemiology in
Systemic Lupus Erythematosus and Rheumatoid
ACR Knowledge Bowl-Final Round ...............................71
Arthritis (#1696-1700, 1062) ...................................79
Personalized Medicine: Transforming 300 Billion Points of Data
Genetics and Genomics of Rheumatic Disease I (#1702-1707) ........79
into Diagnostics, Therapeutics, and New Insights into Disease .......71
Health Services Research, Quality Measures and Quality of Care –
Rheumatology Research Foundation Paul Klemperer, MD, Memorial
Rheumatoid Arthritis (#1708-1713, 195) .........................80
Lectureship: Rheumatoid Arthritis and Autoimmunity: Good Genes,
Imaging in Pediatric Arthritis, Spondyloarthritis, and
Elegant Mechanisms, Bad Results ...............................71
Osteoarthritis (#1714-1719) ...................................81
Navigating the System: The Key to Obtaining Medications for
Metabolic and Crystal Arthropathies II (#1720-1725, 1190) ..........81
Your Patients ................................................71
Rheumatoid Arthritis - Animal Models I (#1726-1731) ..............82
Obesity and Rheumatic Disease .................................71
Rheumatoid Arthritis Treatment - Small Molecules, Biologics
Rheumatic Manifestations of Endocrine Disorders ..................72
and Gene Therapy: Efficacy and Safety of Novel Entities
ACR Plenary Session II: Discovery 2013 (#1732-1737) ................................................82
Abstracts (#1690-1695) ........................................72 Systemic Lupus Erythematosus - Clinical Aspects and
Treatment: Biologic Therapy (#1738-1743) .......................83
ARHP Networking Event
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s -
Networking at Noon ..........................................75
Clinical Aspects and Therapeutics I (#1744-1749) .................84
ACR Sessions Vasculitis II (#1750-1755) ......................................85
ACR Special Session: Career Opportunities in Rheumatology: ACR/ARHP Combined Abstract Session
Making a Choice .............................................75
ACR/ARHP Combined Epidemiology Abstract Session (#1756-1761) ...86
Inter-professional Collaborative Practice and Education: A Review
of the Field and Report of a New Center of Excellence in ARHP Session
Musculoskeletal Care .........................................76 Aerobic, Strength and Biomechanical Considerations for Treatment
Progression in Osteoarthritis: What is the Evidence? ...............86
ACR Meet the Professor Sessions
Designing a Qualitative Study and an Example of the Use of
Challenging Cases in Osteoporosis Management (041) ..............76
Qualitative Study Design in Patients With Rheumatologic Disease ....86
Immunodeficiency Syndromes (042) .............................76
Rheumatic Disease Update Debate: Calcium and Vitamin D,
Macrophage Activation Syndrome (043) ..........................76
What Does the Research Support? ..............................87
Myopathy: Issues in Diagnosis and Treatment (044) ................76
Rheumatic Diseases in Women of Childbearing Years:
Pulmonary Manifestations of Rheumatic Disease (045) ..............76 Fertility, Pregnancy and Lactation ...............................87
Raynaud’s and Digital Ischemia (046) .............................76
ACR/ARHP Workshops
Rheumatoid Arthritis: Biological Agents (047) .....................77
Getting Electronic Health Records Right (226) .....................87
Rheumatoid Arthritis: Safety of Novel Therapies (048) ..............77
Musculoskeletal Exam Skills III: Regional Musculoskeletal
Systemic Lupus Erythematosus: Difficult to Treat Systemic
Examination of the Shoulder and Knee (227) ......................87
Lupus Erythematosus (049) ....................................77
Musculoskeletal Ultrasound (228) ...............................87
What is Not Central Nervous Angiitis: Making the Right
The Rheumatologic Musculoskeletal Screening Exam, With
Diagnosis (050) ..............................................77
Emphasis on Objective Disease-specific Measurements (229) ........87
2013 Program Book 5
TABLE OF CONTENTS
ACR Sessions Capillaroscopy in Rheumatic Diseases Study Group .................98
Bone is Hard or is it? Mechanisms Regulating Bone Qualities .........88 Crystal Study Group ...........................................98
Challenges in Systemic Lupus Erythematosus Management ..........88 Decision Aids in Rheumatology Study Group ......................98
Gout and Pseudogout: What’s New in Treatments and Diagnostic Global Musculoskeletal Health Initiative Study Group ...............98
Modalities? .................................................88 High-Resolution peripheral Quantitative Computed Tomography
Inflammasomes in Health and Disease ...........................88 (HR-pQCT) - Early Damage Detection in Inflammatory and
Degenerative Arthritis Study Group .............................99
Updated ACR Recommendations for the Treatment of Juvenile
Idiopathic Arthritis ...........................................88 JAW (Juvenile Arthritis Workgroup) ..............................99
Latin American Study Group ....................................99
ACR Concurrent Abstract Sessions
Neuro Endocrine Immunology Study Group .......................99
Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and
Pediatric Rheumatology Imaging Study Group .....................99
Angiogenesis II: Mechanisms That contribute to autoimmune
Polymyalgia Rheumatica Study Group ............................99
inflammation (#1762-1767) ....................................89
Primary Sjögren’s Syndrome Study Group .........................99
Epidemiology and Health Services Research II: Healthcare Costs and
Mortality in Rheumatic Disease (#1768-1773) .....................89 Veterans Affairs Rheumatology Study Group ......................99
Muscle Biology, Myositis and Myopathies I: Insights Into Mechanisms Tuesday, October 29, 2013
of the Idiopathic Inflammatory Myopathies (#1774-1779) ...........90 ACR Sessions
Pediatric Rheumatology - Clinical and Therapeutic Aspects II:
Care of Chronic Non-Healing Wounds ...........................100
Autoinflammatory Disease and Systemic Juvenile Idiopathic
Non-coding DNA: Signals, Switches, and Complex Regulation
Arthritis (#1780-1785) ........................................91
of Genes ..................................................100
Rheumatoid Arthritis - Clinical Aspects III: Predictors of Disease
Pediatric Autoimmune and Inflammatory Skin Disease .............100
Course in Rheumatoid Arthritis (#1786-1791) .....................92
ARHP Sessions
Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene
Therapy: Safety & Efficacy of Small Molecule Agents (#1792-1797) ...92 Rheumatic Disease and Pain Management in Special Needs
Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects Populations ................................................100
and Treatment: Therapeutics and Outcomes in Spondyloarthritis Rheumatology Update: Inflammatory Bowel Disease ..............100
(#1798-1803) ................................................93 The Results Section in Medical Research Literature: The
Systemic Lupus Erythematosus - Clinical Aspects: Non-biologic Appropriate and Inappropriate Use of Statistics ..................101
Disease-modifying Antirheumatic Drugs (#1804-1809) .............94 ACR Sessions
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s - Clinical Rheumatology Research Foundation Special Session: Disease
Aspects and Therapeutics II (#1810-1815) ........................94 Targeted Research ..........................................101
ACR Meet the Professor Sessions Risk Management-A Case Study ................................101
Ankylosing Spondylitis: Disease Modification (051) .................95 ACR Meet the Professor Sessions
Basic Immunology for Clinical Rheumatologists (052) ...............95 Ankylosing Spondylitis: 2013 Update (061) .......................101
Pain: Evaluation and Treatment of Back Pain (053) .................95 Antiphospholipid Syndrome (062) ..............................101
Pediatric Rheumatology for Adult Rheumatologists (054) ............95 Crystal: Diagnosis and Management of Gout (063) ................102
Polymyalgia Rheumatica (055) ..................................95 Myopathy: Issues in Diagnosis and Treatment (064) ...............102
Psoriatic Arthritis (056) ........................................95 Osteoporosis: Novel Treatments (065) ..........................102
Pulmonary Hypertension in the Rheumatic Diseases (057) ...........95 Pregnancy and Rheumatic Diseases (066) ........................102
Rheumatoid Arthritis: Challenging Cases (058) .....................96 Rheumatoid Arthritis: Safety of Novel Therapies (067) .............102
Temporal Arteritis (059) .......................................96 Rheumatology Practice 101: Starting Out in Practice for the
Vaccinations for Patients on Biologic Therapies (060) ...............96 Graduating Fellow (068) ......................................102
Systemic Sclerosis: Disease Staging and Subsetting in Clinical
ARHP Sessions
Practice (069) ..............................................102
Body Image with Rheumatic Conditions ..........................96 Temporal Arteritis (070) ......................................102
Rheumatoid Arthritis Management: Views from Around the World ....96
ACR/ARHP Workshops
Work, Health and Well-being: Arthritis and Employment Across
Advanced Musculoskeletal Ultrasound (230) .....................102
the Life Course ..............................................96
Histopathology of Vasculitis (231) ..............................103
ARHP Concurrent Abstract Session
Joint Injections (Knee, Ankle, Shoulder and Wrist) (232) ............103
Rehabilitation Sciences (#1816-1821) ............................97 Knee Braces and Foot Orthosis for Knee Osteoarthritis (233) ........103
ACR Study Groups ACR Session
ACR Musculoskeletal Ultrasound Study Group .....................97 Contract Negotiations for Physicians ............................103
ACR-EULAR Exchange Study Group - Joint Imaging and Beyond .......97 ACR Sessions
Autoantibodies in Diagnosis and Follow-up of Rheumatic Chart Etiquette: Creating Meaningful Notes ......................103
Diseases Study Group .........................................97
Choosing and Monitoring Rheumatoid Arthritis Therapy in 2013 .....103
Behҫet’s Syndrome Study Group ................................98
ACR/ARHP Poster Session C, Thieves’ Market Posters
Biosimilars in Rheumatology Study Group ........................98
and Poster Tours
Abstracts (#1822-2643) ......................................104
6 2013 Program Book
TABLE OF CONTENTS
ACR Sessions Expert Journal Club Study Group ...............................112
Ready or Not… It’s Coming: Implementation of ICD-10 .............104 Gout Classification Criteria Study Group .........................112
The Role of B cells in Rheumatic Disease .........................105 Hypermobility Study Group ...................................113
The Role of Th17 Cells in Health and Disease .....................105 Interstitial Lung Diseases in Connective Tissue Disease Study Group ..113
Macrophage Activation Syndrome Study Group ...................113
ARHP Sessions
Myositis Study Group ........................................113
An Integrative Approach to Pediatric Wellness ....................105
Non-Vasculitic Vasculopathy Study Group ........................113
Anxiety Disorders in Rheumatic Disease .........................105
Osteoarthritis Study Group ....................................113
Immunology Boot Camp Session 3: Biologic Logic, An Update .......105
Spondyloarthritis Study Group .................................113
Knowledge Is Power, but Sample Size Matters More: The Role of
Takayasu’s Arteritis Study Group ...............................113
Sample Size in the Power and Precision of Study Results ...........105
ACR Workshops
Exhibits and Innovation Theater
See page 352 for the complete Innovation Theater listing. Joint Injection Techniques (237) ................................114
Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and
ACR Workshops Clinical Risk Factors: The New Fracture Risk Assessment Algorithm
Musculoskeletal Ultrasound (234) ..............................106 (238). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Tai Chi and Alternative Therapies in Rheumatic (235) ..............106 Renal Histopathology in Systemic Lupus Erythematosus and
The Rheumatologic Musculoskeletal Screening Exam, With Vasculitis (239) .............................................114
Emphasis on Objective Disease-specific Measurements (236) .......106 ACR Session
ACR Session ACR Business Meeting ........................................114
Mechanics, Matrix Disruption, and the Development of ACR Sessions
Osteoarthritis ..............................................106
Adipose Tissue and Inflammation ..............................114
ARHP Sessions Novel Insight Into the Pathogenesis of Systemic Vasculitis ..........114
Nonalcoholic Fatty Liver Disease ...............................106 Osteoporosis Treatment Strategies for Today and Tomorrow ........115
Oral Health in Rheumatologic Disease ...........................106 Vaccinology and DMARD Use in Immunocompromised and
Persistent Pain: Mechanisms of Chronic Pain and Innovative High-Risk Populations ........................................115
Treatment Options ..........................................107
ACR Concurrent Abstract Sessions
ACR Sessions Antiphospholipid Syndrome (#2650-2655) .......................115
Assessment Tool Selection in Health Professions Education .........107 Epidemiology and Health Services Research VI: Risk Factors in
Audits-Are You at Risk? .......................................107 Rheumatic Disease Susceptibility (#2656-2661) ..................116
Protein Citrullination and Biological Response Modification: Health Services Research, Quality Measures and Quality of Care -
Rheumatoid Arthritis and Beyond ..............................107 Innovations in Health Care Delivery (#2662-2667) ................117
Selected Topics Related to Spondylarthropathies ..................107 Osteoarthritis I: Therapeutics in Osteoarthritis (#2668-2673) ........117
Pediatric Rheumatology - Clinical and Therapeutic Aspects III:
ACR Plenary Session III: Discovery 2013
Systemic Lupus Erythematosus and Other Disease Outcomes
Abstracts (#2644-2649) .......................................107
(#2674-2679) ...............................................118
ACR Meet the Professor Sessions Rheumatoid Arthritis - Clinical Aspects IV: Comorbidities in
Adult Inflammatory Myopathy (071) ............................110 Rheumatoid Arthritis (#2680-2685) ............................119
Basic Immunology for Clinical Rheumatologists (072) ..............111 Rheumatoid Arthritis Treatment - Small Molecules, Biologics
and Gene Therapy: Novel Treatment Strategies in Rheumatoid
Behçet’s Disease (073) .......................................111
Arthritis (#2686-2691) .......................................119
Infections with Biologics (074) .................................111
Spondylarthropathies and Psoriatic Arthritis - Pathogenesis,
Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (075) .......111
Etiology (#2692-2697) .......................................120
Psoriatic Arthritis (076) .......................................111
Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II
Rheumatoid Arthritis: Biological Agents (077) ....................111
(#2698-2703) ...............................................121
Rheumatoid Arthritis: Challenging Cases (078) ....................111
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s II:
Systemic Lupus Erythematosus: Lupus Nephritis (079) .............111 Pathogenesis, Animal Models, Genetics: Novel Signaling Pathways
Vasculitis: Update (080) .......................................111 Mediating Fibrosis (#2704-2709). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
ACR Sessions T cell Biology and Targets in Autoimmune Disease (#2710-2714, 710) ... 122
Animal Models in Rheumatic Disease—How Useful Are They? .......111 ARHP Sessions
Hench Lecture: Evolutionary Medicine and Chronic Inflammatory Defining the Roles of the Rheumatology Nurse Internationally ......123
State - Known and New Concepts in Pathophysiology .............112 Inflammatory Arthropathies of the Foot and Ankle: Assessment
Inflammatory Eye Disease: An Update for Rheumatologists .........112 and Non-pharmacological Foot Care Interventions ................123
ACR Study Groups You Can Improve Hand Function in Scleroderma ..................123
A Multi-Disciplinary Approach to Post Fracture Management ARHP Concurrent Abstract Session
Study Group ...............................................112 Clinical Practice/Patient Care (#2716-2721) ......................123
Antiphospholipid Study Group .................................112
2013 Program Book 7
TABLE OF CONTENTS
ACR Workshops The Age of Information Technology: Registries, Administrative
Patient Questionnaires: Multi-Dimensional Health Assessment Databases, and the Role of the Internet in Rheumatic
Questionnaire/Routine Assessment of Patient Index Data 3 Disease Research ...........................................136
and Beyond Toward a Standard, Scientific, Quantitative Patient Industry-Supported Symposia ..............................352
History (240) ...............................................124
Proficiency in Teaching: Engaging Learners (241) ..................124 Wednesday, October 30, 2013
Systemic Sclerosis: How to Perform Skin Scores (242) ..............124
ACR Sessions
ACR Sessions Glycoregulation of Autoimmunity ..............................137
Cell Death and Toll-like Receptor (TLR) Recognition of Nucleic Microparticles: Real Effectors or Just Mini-Me ....................137
Acid Ligands. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124 Rheumatology Roundup: Highlights From the 2013 Annual Meeting ..137
Critical Care Rheumatology ....................................125
ARHP Sessions
International League of Associations for Rheumatology (ILAR) –
Rheumatic Disease Update: Rheumatoid Arthritis .................137
Pediatric Rheumatology in Developing Countries .................125
The Risks, Screening and Management of Human Papillomavirus in
Large Vessel Vasculitis: What Should the Clinician Know ............125
Patients With Rheumatologic Disease ..........................137
Update on Safety Issues in the Treatment of Rheumatic
Diseases – From the FDA and Beyond. . . . . . . . . . . . . . . . . . . . . . . . . . . 125 ACR Session
ACR Concurrent Abstract Sessions Emerging and Unexpected Regulatory Roles for Complement in the
Rheumatic Diseases .........................................137
2013 Rheumatology Research Foundation Edmond L. Dubois, MD
Memorial Lectureship (#2722-2727) ...........................126 ACR Sessions
Biology and Pathology of Bone and Joint II: Osteoclast Biology Current Management of Sjögren’s Syndrome .....................137
and Arthritis (#2728-2733) ...................................126 Molecular and Cellular Profiling of the Immune Response ..........138
Genetics and Genomics of Rheumatic Disease II (#2734-2739) ......127 Patient-reported Outcome Measures for Rheumatologists ..........138
Innate Immunity and Rheumatic Disease (#2740-2745) ............127 Policy Changes That Will Affect Your Practice in 2014: Meaningful
Miscellaneous Rheumatic and Inflammatory Diseases I: Use, Value-based Purchasing, PQRS, and ICD-10 ..................138
Autoinflammatory Syndromes (#2746-2751) .....................128
ACR Concurrent Abstract Sessions
Osteoarthritis II: Risk Factors and Natural History of
B cells in Systemic Lupus Erythematosus (#2794-2799) .............138
Osteoarthritis (#2752-2757) ..................................129
Imaging in Rheumatoid Arthritis (#2800-2805) ....................139
Rheumatoid Arthritis - Clinical Aspects V: Observational Studies
in Rheumatoid Arthritis (#2758-2763) ..........................129 Infection Related Rheumatic Diseases (#2806-2811) ...............140
Rheumatoid Arthritis Treatment - Small Molecules, Biologics Medical Education (#2812-2817) ...............................140
and Gene Therapy: Efficacy of Approved Biologics I (#2764-2769) ...130 Rheumatoid Arthritis - Animal Models II (#2818-2823) .............141
Sjögren’s Syndrome: Basic Science (#2770-2775) ..................131 Rheumatoid Arthritis - Clinical Aspects VI: Cardiovascular Disease in
Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Rheumatoid Arthritis (#2824-2829) ............................142
Treatment: Clinical Features of Spondylarthritis (#2776-2781) ......132 Systemic Lupus Erythematus Clinical Aspects: Pregnancy
Vasculitis III (#2782-2787) .....................................132 (#2830-2835) ...............................................142
Spondylarthropathies and Psoriatic Arthritis:
ACR Meet the Professor Sessions
Clinical Aspects and Treatment: Clinical and Imaging Aspects
Controversies in Sjögren’s Syndrome (081) .......................134 of Axial Spondyloarthritis (#2836-2841) .........................143
Osteoarthritis: Update 2013 (082) ..............................134
ARHP Sessions
Pulmonary Manifestations of Rheumatic Disease (083) .............134
Rheumatology Practice in the Age of the Affordable Care Act .......144
Raynaud’s and Digital Ischemia (084) ............................134
Update on Orthotic Management for Rheumatic Diseases
Reactive Arthritis: An Update (085) .............................134
Through the Lifespan ........................................144
Still’s Disease and Autoinflammatory Syndromes (086) .............134
ARHP Concurrent Abstract Session
Systemic Lupus Erythematosus: Central Nervous System (087) ......134
Systemic Lupus Erythematosus: Difficult to Treat Education/Community Programs (#2842-2847) ...................144
Systemic Lupus Erythematosus (088) ...........................134 ACR Sessions
Understanding of Approach to the Care of Patients
2013 ACR-EULAR Scleroderma Classification Criteria ...............145
With Vasculitis (089) .........................................134
PCMH-Model and the Rheumatology Specialty ...................145
Vaccinations for Patients on Biologic Therapies (090) ..............135
ACR Concurrent Abstract Sessions
ACR/ARHP Combined Abstract Session
Fibromyalgia, Soft Tissue Disorders and Pain: Treatment and
ACR/ARHP Combined Pediatrics Abstract Session (#2788-2793). . . . . . 135
Outcome Assessment (#2848-2852, 121) ........................145
ARHP Sessions Orthopedics, Low Back Pain, Rehabilitation and Mechanisms of
Enhancing Clinical Practice with Patient Engagement and Pain in Arthritis (#2854-2859) .................................146
Self-management Support Strategies ...........................136 Pediatric Rheumatology - Pathogenesis and Genetics (#2860-2865) ..147
Pharmacist-Physician Partnership in Rheumatic Disease Rheumatoid Arthritis - Clinical Aspects VII: Remission, Flare and
Management ...............................................136 Outcome Measures in Rheumatoid Arthritis (#2866-2871) .........147
Rheumatoid Arthritis - Pathogenetic Pathways (#2872-2877) ........148
8 2013 Program Book